EA202092459A1 - Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают - Google Patents

Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают

Info

Publication number
EA202092459A1
EA202092459A1 EA202092459A EA202092459A EA202092459A1 EA 202092459 A1 EA202092459 A1 EA 202092459A1 EA 202092459 A EA202092459 A EA 202092459A EA 202092459 A EA202092459 A EA 202092459A EA 202092459 A1 EA202092459 A1 EA 202092459A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
interleukin
therapeutic application
hybrid proteins
Prior art date
Application number
EA202092459A
Other languages
English (en)
Russian (ru)
Inventor
Ян-Синь Фу
Хуа Пэн
Диюань Сюэ
Original Assignee
Иммьюн Таргетинг Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммьюн Таргетинг Инк. filed Critical Иммьюн Таргетинг Инк.
Publication of EA202092459A1 publication Critical patent/EA202092459A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA202092459A 2018-04-25 2019-04-24 Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают EA202092459A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810376920.1A CN110396133B (zh) 2018-04-25 2018-04-25 一种以白介素12为活性成分的融合蛋白型药物前体
PCT/US2019/028933 WO2019209965A2 (en) 2018-04-25 2019-04-24 Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof

Publications (1)

Publication Number Publication Date
EA202092459A1 true EA202092459A1 (ru) 2021-06-15

Family

ID=68294664

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092459A EA202092459A1 (ru) 2018-04-25 2019-04-24 Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают

Country Status (9)

Country Link
US (1) US12473337B2 (cg-RX-API-DMAC7.html)
JP (2) JP2021521822A (cg-RX-API-DMAC7.html)
KR (1) KR20210024446A (cg-RX-API-DMAC7.html)
CN (2) CN110396133B (cg-RX-API-DMAC7.html)
AU (1) AU2019261411B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020021791A2 (cg-RX-API-DMAC7.html)
CA (1) CA3097995A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092459A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019209965A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
AU2020316002B2 (en) * 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
EP4251187A4 (en) * 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
WO2022129313A1 (en) * 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Precursor proteins and kit for targeted therapy
WO2022204267A1 (en) * 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same
WO2022226073A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides and methods of use thereof
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
AU2024207005A1 (en) * 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
EP4695282A1 (en) 2023-04-12 2026-02-18 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
CN122349538A (zh) * 2023-12-07 2026-07-07 上海药明生物技术有限公司 针对il-12受体的异二聚体蛋白
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025256578A1 (zh) * 2024-06-12 2025-12-18 龙启生物制药(杭州)有限公司 Treg细胞靶向IL12融合蛋白及其制备、治疗方法
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
AU1407997A (en) * 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1835030A1 (en) 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
JP4718274B2 (ja) 2005-08-25 2011-07-06 東京エレクトロン株式会社 半導体製造装置,半導体製造装置の流量補正方法,プログラム
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN105218682B (zh) * 2015-10-26 2019-05-07 杨晶 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
EP3511340B1 (en) * 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
CN110396133B (zh) 2021-07-23
CN110396133A (zh) 2019-11-01
WO2019209965A3 (en) 2019-12-05
JP2021521822A (ja) 2021-08-30
KR20210024446A (ko) 2021-03-05
WO2019209965A2 (en) 2019-10-31
US20220162280A1 (en) 2022-05-26
CN112638938A (zh) 2021-04-09
JP2025032113A (ja) 2025-03-11
EP3810639A2 (en) 2021-04-28
AU2019261411B2 (en) 2024-11-14
CA3097995A1 (en) 2019-10-31
AU2019261411A1 (en) 2020-11-26
US12473337B2 (en) 2025-11-18
BR112020021791A2 (pt) 2021-02-23

Similar Documents

Publication Publication Date Title
WO2019209965A3 (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
MX2021013126A (es) Variantes de il-15 y usos de las mismas.
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
UA130113C2 (uk) Мутеїн інтерлейкіну-21
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
EA202090372A1 (ru) Универсальные соединения авт и их применение
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
EA202090817A1 (ru) Триспецифические белки и способы их применения
EA202190453A1 (ru) Полиспецифические связывающие белки, которые связываются с her2, nkg2d и cd16, и способы их применения
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA202092086A1 (ru) Ингибиторы аргиназы
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202192888A1 (ru) Соединения и способы нацеливания на тау человека
MX2024005705A (es) Composiciones de liquidos ionicos.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
EA202092162A1 (ru) Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EA202192488A1 (ru) Антитела против tsg-6 и их применения
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения